BioDlink International Announces Board and Committee Restructuring
BioDlink International Company Limited has announced a restructuring of its board and committees effective October 11, 2025. Mr. Fu Shan will chair the Strategy and ESG Committee, with Dr. Liu Weidong, Ms. Sun Hui, Mr. Zhang Qing, and Dr. Gu Xuelin taking roles in various committees. This restructuring aims to improve governance and strategic oversight. The current analyst rating for TOT BIOPHARM International Co. Ltd. (HK:1875) is a Hold with a price target of HK$2.00.
An announcement from TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) is now available.
BioDlink International Company Limited, incorporated in Hong Kong, has announced changes to its board of directors and the composition of its board committees. Effective from October 11, 2025, Mr. Fu Shan will serve as the Chairperson of the Strategy and ESG Committee, while Dr. Liu Weidong, Ms. Sun Hui, Mr. Zhang Qing, and Dr. Gu Xuelin will take on various roles across the Audit and Connected Transactions Review, Remuneration, and Nomination Committees. These changes are expected to enhance the governance and strategic oversight of the company.
The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
More about TOT BIOPHARM International Co. Ltd.
Average Trading Volume: 411,897
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.66B
Find detailed analytics on 1875 stock on TipRanks’ Stock Analysis page.
